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The continuing saga of the aetiology and pathogenesis of
joint destruction in rheumatoid arthritis (RA) has often led
to reassessment of the working hypotheses created to
explain the phenomenon. Initial and current models set a
protagonistic role for inflammatory and autoimmune cellu-
lar mediators in RA, and this notion has been well sup-
ported by a plethora of experimental data. However, it may
have been biased by the relatively more easy access to
experimental and clinical data regarding immune cell func-
tion and also, perhaps, by the overenthusiasm with which
it was felt cellular immunology could explain chronic
immunopathologies. Even from early investigations,
however, it has been clear that for arthritis development,
inflammatory and autoimmune processes actively inter-
acted with a network of non-immune cell types, and that it
was the effector activities of these cell types that resulted
in cartilage and bone attack. Although, until recently, the
non-immune constituents of the synovial lining were
regarded as mere targets of the inflammatory milieu and as
secondary players in the development of disease, more
recent data provide serious grounds for considering these
cells as dominant players in the aetiopathogenesis of RA.
The series of reviews on synovial fibroblasts (SFs) pre-
sented in this issue of Arthritis Research aims to refocus
attention on our current knowledge of the biology of SFs
and their possible involvement in the development of RA.
One major drawback in our understanding of the role of
synovial lining cells, and particularly of SFs in RA, has
been the lack of information regarding the origins and
functions of this cell type. Despite years of intensive RA
research, it is still unclear which cell type is defined by the
term ‘synovial fibroblast’. In the first review article [1],
some of the characteristics of this mysterious cell type in
terms of development and differentiation are discussed.
Although difficult to document in culture, it seems that,
physiologically, SFs comprise mesenchyme-derived popu-
lations that display heterogeneous tissue localization
(intimal and subintimal), reflecting differential activation
and differentiation states. An intriguing functional property
of SFs may stem from their resemblance to bone marrow
stromal cells: both cell types share common progenitors
and display similar gene expression signatures. It is there-
fore likely that, similar to the bone marrow stromal cells,
SFs may support or modulate the effector character of
resident or blood-derived cells in the arthritic joint. This is
further supported by the fact that intimal SFs are normally
in minimal contact with immune cells, including
macrophages and lymphocytes. Topographical separation
may therefore provide a first degree of protection against
deleterious SF–immune cell interactions. In a RA joint,
both the localization and the interactions of SFs with
leukocytes are altered, allowing for the development of
effector functions and of pathogenic inflammation.
The complexity of the responses of normal, activated or
RA SFs is governed by the differential signals emanating
from the extracellular milieu. This complexity in responses
is reflected in the differential expression profiles of adhe-
sion molecules, cytokines and chemokines, extracellular
matrix degrading enzymes and angiogenic factors that
result in the response to haemopoietic and stromal cell
derived factors. In the second review [2], a number of
such factors known to interact with SFs either in vivo or
following stimulation in vitro, which also modulate their
phenotype and function, are discussed.http://arthritis-research.com/content/2/5/342
In response to extracellular factors, SFs themselves
release a plethora of effector molecules interacting with a
variety of cells and promoting matrix degradation. Several
important scenarios are described in the third review [3].
First, SFs instigate leukocyte attraction and homing
through the expression of chemokines like MIP-1,
RANTES, interleukin-8 and interleukin-16. SFs can also
support myeloid and lymphoid cell growth via the secre-
tion of various colony stimulating factors, as well as their
own growth via the production of platelet derived growth
factor. However, the most classical effector function of RA
SFs is their capacity to interact with the extracellular matrix
and cause its degradation via the production of matrix
metalloproteinases and cathepsins. This process seems to
be autonomously regulated since it is now clear that it
does not require immune effector cells. Interestingly, SFs
may also be able to dampen the immune response via the
production of transforming growth factor-b, soluble tumour
necrosis factor receptors and interleukin-10, as well as
extracellular matrix degradation by tissue inhibitor of metal-
loproteins. In an analogous fashion to regulatory T cells,
this seeming paradox may in fact reflect the presence of
different populations of regulatory SFs present in a RA
joint that are yet to be defined. Recent data also provide
another intriguing role for the SFs, which are clearly pro-
ducing factors supporting angiogenesis such as trans-
forming growth factor-b, platelet derived growth factor,
granulocyte macrophage colony stimulating factor, epider-
mal growth factor, vascular endothelial growth factor and
fibroblast growth factor. Since angiogenic support is a
distinctive property of cancer cells, it provides support for
the older speculation that RA SFs could in fact be malig-
nant cells, which is now further supported by the recent
demonstration that angiogenesis inhibitors are able to
ameliorate arthritis development in a mouse model.
The potential of RA SFs to behave as transformed cells is
also documented by their expression of intracellular prod-
ucts able to modulate the cell cycle. For example, as dis-
cussed in the fourth review [4], the levels and activation
patterns of AP-1 and p53 gene products may, at least in
part, be responsible for the aggressive, proliferative and
cartilage attacking properties of RA SFs. In support of the
malignancy hypothesis is the notion that synovial hyperpla-
sia results from increased proliferation of RA SFs either
spontaneously or in response to cytokines, with the
increased expression of c-myc, c-jun and nuclear factor
kB factors indicating that hyperproliferation may indeed
occur. However, although this appears to be a widely
accepted property of RA SFs in culture, it is not clear if
proliferation occurs in vivo. An alternative explanation to
hyperproliferation is defective apoptosis. Apoptotic signals
provided by molecules such as PTEN, c-myc, p16 and
SENTRIN have been reported as reduced in RA SFs, and
these cells show reduced apoptosis in situ. Resistance to
apoptosis may also result from desensitization of both Fas
and tumour necrosis factor receptor pathways. The upreg-
ulation of transcription factor complexes such as nuclear
factor  kB and AP-1 indicate increased transcriptional
activities in RA SFs. Interestingly, most of the disease-
associated products like cytokines and matrix metallopro-
teinases are controlled by these transcription factors. It is
logical, although still speculative, to assume that muta-
tions/events leading to distorted signalling from these
modules may result in altered cytokine patterns and effec-
tor responses by SFs.
It is clear that the field of synovial fibroblast research is still
in its infancy. Although there is sufficient information to
support the role of SFs as a major contributor to joint
degradation, their functional role in modulating the patho-
genic inflammatory and autoimmune responses in RA
joints remains poorly defined. Are SFs capable of initiating
the arthritic reactions or is their role merely supportive?
How do these cells affect macrophage activation and
homing? Can they also affect local lymphocyte responses,
and what may be the outcome? Is the SF response multi-
clonal or monoclonal? Are there distinct functions in the
different types of SFs and can we hope that regulatory
SFs may exist?
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